Navigation Links
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Date:5/12/2008

ly spread to countries not previously affected.

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006. The Market Authorization Application (MAA) in Europe as well as the Biological License Application (BLA) with the US Food and Drug Administration (FDA) for the use of the vaccine to prevent Japanese Encephalitis were submitted in December of 2007. The licensure application to TGA (Therapeutic Goods Administration) in Australia was submitted in February of 2008.

The Company's broad development pipeline includes a partnered S. aureus vaccine in Phase II, a therapeutic vaccine against Hepatitis C in Phase II, a Pseudomonas vaccine in Phase II, a partnered Tuberculosis vaccine (Phase I/II), and five products focused on infectious diseases in preclinical development.

Intercell is listed on the Prime Market of the Vienna Stock Exchange under the symbol "ICLL".
ISIN: AT0000612601

For more information on Intercell, please visit: http://www.intercell.com

About Iomai Corporation:

Iomai Corporation has approximately 110 employees and discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015 Perrigo Company plc (NYSE: PRGO ... Healthcare Products®," today announced that it has completed the ... a cash and equity transaction valued at approximately €3.8 ... debt. Sellers are Marc Coucke , Waterland Private ...   "The combination of Perrigo and ...
(Date:3/30/2015)... 30, 2015  Caris Life Sciences® today announced the ... pathways may have potentially significant benefit in a select ... were highlighted today in an oral presentation in a ... 2015 Annual Meeting on Women,s Cancer in ... one of four presented at the annual meeting that ...
(Date:3/30/2015)... , March 30, 2015  Orexigen Therapeutics, ... Tom Cannell has joined as Chief ... commercialization of Contrave® /Mysimba™ (naltrexone HCl / bupropion ... of Orexigen,s global commercial strategy, assuming responsibilities previously ... leading Orexigen,s commercial effort through the U.S. launch ...
Breaking Medicine Technology:Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 2Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 3Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 2Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 5Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 6Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 8Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 9Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 10
... 2012 Amsterdam Molecular Therapeutics (Euronext: AMT), ... announced that the Extraordinary General Meeting (EGM) of shareholders ... with the EGM Notice of February 17, 2012. At ... the substantial corporate restructuring and financing transaction, which will ...
... DIEGO, March 30, 2012  Genalyte, Inc., a life ... technology, today announced completion of an $11.8 million ... Claremont Creek Ventures and private investors from Genalyte,s ... financing.  Genalyte intends to use the new funds ...
Cached Medicine Technology:Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 3
(Date:3/31/2015)... 31, 2015 “ Prong ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how this phone ... Everyone knows that feeling when their phone is running out ... a new phone case that is a solution to this ...
(Date:3/31/2015)... With nationwide predictions of major floods due to ... pineapple express, the OPP is urging its insureds to ... , "Protecting Your Business" 09/23/2014, provides alarming statistics about ... business. , Here are 3 statistics that every business ... small businesses never reopen their doors after a flood ...
(Date:3/30/2015)... MA (PRWEB) March 31, 2015 ... mobility management services, has been announced as one of ... annual list the fastest-growing private companies in Massachusetts. ... the state’s fastest revenue growth from 2011 through 2014. ... the Boston Business Journal has recognized Wireless Analytics’s revenue ...
(Date:3/30/2015)... City, NY (PRWEB) March 31, 2015 ... Owner / Operator for Diamond Pharmacy Services, ... Ms. Mitchell is recognized with this prestigious distinction ... networking organization of professional women in the country, ... Association of Professional Women is a powerfully vibrant ...
(Date:3/30/2015)... 2015 The AAAHC, a private, ... the provision of high-quality health care through the ... and accreditation programs for 35 years. Through a ... to promote excellence in patient safety and care. ... and on-site evaluations by AAAHC expert surveyors, doctors, ...
Breaking Medicine News(10 mins):Health News:The Swiss Army Knife of Phone Cases was Featured on NewsWatch Television 2Health News:3 Statistics Every Business Owner Should Know About Flood Waters and Flood Insurance, from the Optometric Protector Plan® 2Health News:Wireless Analytics Growth Streak Continues; Named to Boston Business Journal’s Pacesetters Second Year In a Row 2Health News:Wireless Analytics Growth Streak Continues; Named to Boston Business Journal’s Pacesetters Second Year In a Row 3Health News:National Association of Professional Women Announces Tamara Mitchell, Owner / Operator of Diamond Pharmacy Services, a 2015 Professional Woman of the Year 2Health News:Precinct Ambulatory Surgery Center Achieves Accreditation Association for Ambulatory Health Care Accreditation 2
... interests of pain patients in light of federal pain management ... American Academy of Pain Medicine (AAPM) will brief congress today ... , The crisis of under-treated pain extends well ... It is now a social issue with major economic and ...
... DATA ), a technology and services company focused ... reported its,operating results for the third quarter and first ... ended September 30, 2007, revenue decreased 52% to,$2,116,000, and ... $(0.26),per share on a basic and diluted basis. These ...
... CHICAGO, Nov. 8 Allscripts, the leading,provider of ... to improve healthcare, today announced results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ) Total revenue for ... $73.4,million, a record for the company, compared to ...
... Develop Rapid Molecular ... -, SAN DIEGO, Nov. 8 Gen-Probe (Nasdaq: ... no longer intends to,fund the companies, collaboration to develop rapid ... formally terminate the,collaboration in the coming days. "Gen-Probe continues ...
... Revenue Growth, Expanding Installed Base and ... Data Around the Use of IVUS, SAN DIEGO, Nov. ... of intravascular ultrasound (IVUS) and,functional measurement (FM) products designed to ... today reported results,for the third quarter and first nine months ...
... ... Biologics to Biotest, BOCA RATON, Fla., Nov. 8 ... results. The company recorded a net loss of $15.9 million, or,$0.26 ... million, or $0.12 per share, of expenses for unusual items described,below. ...
Cached Medicine News:Health News:National physician organization supports Capps-Rogers Bill at today's congressional briefing 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 8Health News:Allscripts Reports Third Quarter 2007 Results 2Health News:Allscripts Reports Third Quarter 2007 Results 3Health News:Allscripts Reports Third Quarter 2007 Results 4Health News:Allscripts Reports Third Quarter 2007 Results 5Health News:Allscripts Reports Third Quarter 2007 Results 6Health News:Allscripts Reports Third Quarter 2007 Results 7Health News:Allscripts Reports Third Quarter 2007 Results 8Health News:Allscripts Reports Third Quarter 2007 Results 9Health News:Allscripts Reports Third Quarter 2007 Results 10Health News:Allscripts Reports Third Quarter 2007 Results 11Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 2Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 3Health News:Volcano Reports Record Third Quarter Revenues 2Health News:Volcano Reports Record Third Quarter Revenues 3Health News:Volcano Reports Record Third Quarter Revenues 4Health News:Volcano Reports Record Third Quarter Revenues 5Health News:Volcano Reports Record Third Quarter Revenues 6Health News:Volcano Reports Record Third Quarter Revenues 7Health News:Volcano Reports Record Third Quarter Revenues 8Health News:Volcano Reports Record Third Quarter Revenues 9Health News:Volcano Reports Record Third Quarter Revenues 10Health News:Volcano Reports Record Third Quarter Revenues 11Health News:Volcano Reports Record Third Quarter Revenues 12Health News:Volcano Reports Record Third Quarter Revenues 13Health News:Volcano Reports Record Third Quarter Revenues 14Health News:Volcano Reports Record Third Quarter Revenues 15Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 2
Steroid eluting pacemaker leads...
... family of temporary sensing and pacing leads. ... in temporary pacing leads and improved upon ... use and less traumatic to heart tissue. ... Pacing Lead is designed for temporary atrial ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: